Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 27

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 4I
Chunk 27
---
(epcoritamab)​   CD3xCD20   Co-developmentGenmab/AbbVie    Approved in multiple territories including the U.S. and Europe for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy and in Japan for adult patients with certain types of relapsed or refractory large B-cell lymphoma (“LBCL”) after two or more lines of systemic therapy
​                                                               ​          ​                              Approved in multiple territories including the U.S. and Europe for adult patients with relapsed or refractory FL after two or more lines of systemic therapy                                                                                                                                                           
Tivdak(tisotumab vedotin-tftv)                                  TF         Co-development Genmab/Pfizer   Approved in the U.S. for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy                                                                                                                                                                                    
​
​
​

40

<{self.tag} alt="{self.alt}" src="{self.src}">Pipeline, Including Further Development for Approved Medicines
In 2024, Genmab discontinued the GEN1047 (DuoBody-CD3xB7H4), GEN3017 (DuoBody-CD3xCD30) and GEN1056 (with BioNTech, BNT322) programs following a strategic re-evaluation of Genmab’s portfolio. For similar reasons, Genmab and BioNTech took the decision to discontinue the clinical development of GEN1053 (HexaBody-CD27, BNT313) including the Phase I/II clinical trial (NCT05435339) in solid tumors. 
Epcoritamab 
Epcoritamab is a proprietary bispecific antibody therapeutic created using our proprietary DuoBody technology platform. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically validated target on malignant B-cells. We used technology licensed from Medarex, Inc. (“Medarex”) to generate the CD20 antibody forming part of epcoritamab. We are co-developing, and co-commercializing in the U.S. and Japan, epcoritamab in collaboration with AbbVie. The companies have a broad clinical development program for epcoritamab including five ongoing Phase III trials and additional trials in planning. Epcoritamab is marketed as EPKINLY in the U.S., Japan, and other regions, and as TEP